Using humanized P301S tau transgenic mouse models of AD, we found that PS19 mice exhibit elevated m6A levels in the cortex and hippocampus at 9 months compared to age-matched WT and levels increased further from 6 to 9 months. Here, MAPT is linked to Alzheimer disease.